These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 28215938)
1. Limitations of cholesterol lowering with PCSK9 inhibitors. Thompson G Lancet Diabetes Endocrinol; 2017 Apr; 5(4):241-243. PubMed ID: 28215938 [No Abstract] [Full Text] [Related]
2. Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol. Della Badia LA; Elshourbagy NA; Mousa SA Pharmacol Ther; 2016 Aug; 164():183-94. PubMed ID: 27133571 [TBL] [Abstract][Full Text] [Related]
3. So low… so far so good: neurocognitive impact of lowering LDL-C levels with PCSK9 inhibitors. Gencer B; Mach F Eur Heart J; 2018 Feb; 39(5):382-384. PubMed ID: 29346544 [No Abstract] [Full Text] [Related]
4. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy. Joseph L; Robinson JG Prog Cardiovasc Dis; 2015; 58(1):19-31. PubMed ID: 25936907 [TBL] [Abstract][Full Text] [Related]
5. Proprotein convertase subtilisin / kexin 9 (PCSK9) inhibitors and the future of dyslipidemia therapy: an updated patent review (2011-2015). Elbitar S; Khoury PE; Ghaleb Y; Rabès JP; Varret M; Seidah NG; Boileau C; Abifadel M Expert Opin Ther Pat; 2016 Dec; 26(12):1377-1392. PubMed ID: 27359211 [TBL] [Abstract][Full Text] [Related]
6. Eligibility for PCSK9 treatment in 734 Hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥ 70 mg/dl despite maximal tolerated cholesterol lowering therapy. Glueck CJ; Shah P; Goldenberg N; Prince M; Lee K; Jetty V; Kumar A; Goldenberg M; Wang P Lipids Health Dis; 2016 Mar; 15():55. PubMed ID: 26968977 [TBL] [Abstract][Full Text] [Related]
12. [Proprotein convertase subtilisin/kexin type 9 (PCSK9) and inhibitors]. Avci A; Demir K; Altunkeser BB Turk Kardiyol Dern Ars; 2014 Oct; 42 Suppl 2():56-67. PubMed ID: 25693363 [TBL] [Abstract][Full Text] [Related]
13. Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies. Rey J; Poitiers F; Paehler T; Brunet A; DiCioccio AT; Cannon CP; Surks HK; Pinquier JL; Hanotin C; Sasiela WJ J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27287699 [TBL] [Abstract][Full Text] [Related]
14. PCSK9 inhibitors and LDL reduction: pharmacology, clinical implications, and future perspectives. Fitzgerald G; Kiernan T Expert Rev Cardiovasc Ther; 2018 Aug; 16(8):567-578. PubMed ID: 29979908 [TBL] [Abstract][Full Text] [Related]
15. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons. Yadav K; Sharma M; Ferdinand KC Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986 [TBL] [Abstract][Full Text] [Related]
16. An update on the clinical development of proprotein convertase subtilisin kexin 9 inhibitors, novel therapeutic agents for lowering low-density lipoprotein cholesterol. Ling H; Burns TL; Hilleman DE Cardiovasc Ther; 2014 Apr; 32(2):82-8. PubMed ID: 24354905 [TBL] [Abstract][Full Text] [Related]
17. The Role of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in the Management of Dyslipidemia. Tziomalos K Curr Pharm Des; 2017; 23(10):1495-1499. PubMed ID: 28155622 [TBL] [Abstract][Full Text] [Related]
18. Targeting low-density lipoprotein cholesterol with PCSK9 inhibitors. Scherer DJ; Nelson AJ; Psaltis PJ; Nicholls SJ Intern Med J; 2017 Aug; 47(8):856-865. PubMed ID: 28401639 [TBL] [Abstract][Full Text] [Related]
19. Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors and Cardiovascular Risk: Does a Further Analysis of the Fourier Trial Suggest Changes in the Target of Lipid Lowering Therapy? Cervelli N; Tocci G; Ferri C High Blood Press Cardiovasc Prev; 2018 Mar; 25(1):5-7. PubMed ID: 29305812 [No Abstract] [Full Text] [Related]
20. [PCSK9 Inhibitors - the magic bullet for LDL cholesterol reduction?]. Richter K; Barthel A; Bornstein SR; El-Armouche A; Wagner M Dtsch Med Wochenschr; 2016 Jun; 141(12):863-9. PubMed ID: 27305302 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]